252 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
3
Isolation and structure of SCH 351633: a novel hepatitis C virus (HCV) NS3 protease inhibitor from the fungus Penicillium griseofulvum.
Schering-Plough Research Institute
5
Phenylalanine and Phenylglycine Analogues as Arginine Mimetics in Dengue Protease Inhibitors.
Heidelberg University
19
Dual inhibitors of the dengue and West Nile virus NS2B-NS3 proteases: Synthesis, biological evaluation and docking studies of novel peptide-hybrids.
Heidelberg University
4
Discovery of HCV NS5B thumb site I inhibitors: core-refining from benzimidazole to indole scaffold.
Shandong University
30
Vinylated linear P2 pyrimidinyloxyphenylglycine based inhibitors of the HCV NS3/4A protease and corresponding macrocycles.
TBA
8
Identification of novel thiadiazoloacrylamide analogues as inhibitors of dengue-2 virus NS2B/NS3 protease.
China Pharmaceutical University
21
A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, West Nile and Chikungunya viruses.
University of Kwazulu-Natal
39
C-terminal residue optimization and fragment merging: discovery of a potent Peptide-hybrid inhibitor of dengue protease.
Heidelberg University
11
Structure-based design of a novel series of azetidine inhibitors of the hepatitis C virus NS3/4A serine protease.
Idenix Pharmaceuticals
1
Macrocyclic inhibitors of 3C and 3C-like proteases of picornavirus, norovirus, and coronavirus.
Wichita State University
15
Synthesis and evaluation of tripeptidyl alpha-ketoamides as human rhinovirus 3C protease inhibitors.
Eli Lilly
2
Synthesis and biological characterization of B-ring amino analogues of potent benzothiadiazine hepatitis C virus polymerase inhibitors.
Abbott Laboratories
1
Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors.
Uppsala University
1
Synthesis and antiviral activity of 5-substituted cytidine analogues: identification of a potent inhibitor of viral RNA-dependent RNA polymerases.
The Pennsylvania State University
28
Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: from benzimidazole to indole scaffolds.
Boehringer Ingelheim Pharmaceuticals
4
Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of fingerroot, Boesenbergia rotunda (L.), towards dengue-2 virus NS3 protease.
Sunway University College
6
Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
Schering-Plough Research Institute
3
Antiviral compounds from traditional Chinese medicines Galla Chinese as inhibitors of HCV NS3 protease.
Peking University
22
Solid-phase library synthesis, screening, and selection of tight-binding reduced peptide bond inhibitors of a recombinant Leishmania mexicana cysteine protease B.
Carlsberg Laboratory
13
Specific inhibition of HIV-1 protease by boronated porphyrins.
University of California
28
HIV protease: a novel chemotherapeutic target for AIDS.
Merck Sharp and Dohme Research Laboratories
16
Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain.
Uppsala University
2
NMR line-broadening and transferred NOESY as a medicinal chemistry tool for studying inhibitors of the hepatitis C virus NS3 protease domain.
Boehringer Ingelheim Pharmaceuticals
21
Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors.
Boehringer Ingelheim Pharmaceuticals
27
Peptide-based inhibitors of the hepatitis C virus serine protease.
Boehringer Ingelheim (Canada)
18
Peptidomimetic inhibitors of human immunodeficiency virus protease (HIV-PR): Design, enzyme binding and selectivity, antiviral efficacy, and cell permeability properties
TBA
32
Structure-activity relationship and improved hydrolytic stability of pyrazole derivatives that are allosteric inhibitors of West Nile Virus NS2B-NS3 proteinase.
Sanford-Burnham Medical Research Institute
19
Non-nucleoside inhibitors of HCV polymerase NS5B. Part 3: synthesis and optimization studies of benzothiazine-substituted tetramic acids.
Roche Palo Alto
13
Non-nucleoside inhibitors of HCV polymerase NS5B. Part 4: structure-based design, synthesis, and biological evaluation of benzo[d]isothiazole-1,1-dioxides.
Roche Palo Alto
10
Inhibition of human cytomegalovirus protease by benzoxazinones and evidence of antiviral activity in cell culture
TBA
6
Synthesis and activity of conformationally-constrained macrocyclic norstatine-based inhibitors of HIV protease
TBA
5
Structure-activity relationships of heteroaromatic esters as human rhinovirus 3C protease inhibitors.
Institute of Science and Technology
1
Identification of halosalicylamide derivatives as a novel class of allosteric inhibitors of HCV NS5B polymerase.
Abbott Laboratories
4
PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications.
Medical University of Lublin
11
Ringing medicinal chemistry: The importance of 3-membered rings in drug discovery.
Monash University (Malaysia Campus)
1
Design, synthesis, and biological evaluation of a series of new anthraquinone derivatives as anti-ZIKV agents.
Sun Yat-sen University
2
Inhibition of dengue viruses by N-methylcytisine thio derivatives through targeting viral envelope protein and NS2B-NS3 protease.
Kuang Tien General Hospital
12
Perspectives on the current antiviral developments towards RNA-dependent RNA polymerase (RdRp) and methyltransferase (MTase) domains of dengue virus non-structural protein 5 (DENV-NS5).
Csir-Indian Institute of Chemical Technology (CSIR-IICT)
3
Recent two-year advances in anti-dengue small-molecule inhibitors.
Macao University of Science and Technology
5
Discovery of dehydroandrographolide derivatives with C19 hindered ether as potent anti-ZIKV agents with inhibitory activities to MTase of ZIKV NS5.
Nanjing Tech University
15
N-sulfonyl peptide-hybrids as a new class of dengue virus protease inhibitors.
Heidelberg University
5
Designing photoaffinity tool compounds for the investigation of the DENV NS2B-NS3 protease allosteric binding pocket.
Johannes Gutenberg-University
2
Design, synthesis, and biological evaluation of novel 2'-methyl-2'-fluoro-6-methyl-7-alkynyl-7-deazapurine nucleoside analogs as anti-Zika virus agents.
Guangzhou Institutes of Biomedicine and Health
8
Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors.
Peking University
13
P2-P4 macrocyclic inhibitors of hepatitis C virus NS3-4A serine protease.
Schering-Plough Research Institute
19
Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b polymerase binding site.
Wyeth Research
1
SAR evolution towards potent C-terminal carboxamide peptide inhibitors of Zika virus NS2B-NS3 protease.
Irbm
13
Insights on Dengue and Zika NS5 RNA-dependent RNA polymerase (RdRp) inhibitors.
Federal University of Alagoas
53
SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase.
Amgen
113
3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase.
Glaxosmithkline
18
Design and synthesis of 3,4-dihydro-1H-[1]-benzothieno[2,3-c]pyran and 3,4-dihydro-1H-pyrano[3,4-b]benzofuran derivatives as non-nucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase.
Wyeth Research
30
Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors.
Novartis Institute For Tropical Diseases
12
Peptide inhibitors of Dengue virus NS3 protease. Part 1: Warhead.
Novartis Institute For Tropical Diseases
7
Design, synthesis, and biological activity of m-tyrosine-based 16- and 17-membered macrocyclic inhibitors of hepatitis C virus NS3 serine protease.
Schering-Plough Research Institute
6
Synthesis and biological activity of macrocyclic inhibitors of hepatitis C virus (HCV) NS3 protease.
Schering-Plough Research Institute
24
Investigation of glycine alpha-ketoamide HCV NS3 protease inhibitors: effect of carboxylic acid isosteres.
Pharmaceutical Research Institute
30
Discovery of potent benzoxaborole inhibitors against SARS-CoV-2 main and dengue virus proteases.
Heidelberg University
40
Anchor-GRIND: filling the gap between standard 3D QSAR and the GRid-INdependent descriptors.
Imim/Universitat Pompeu Fabra
12
Seeking heterocyclic scaffolds as antivirals against dengue virus.
National Institute of Technology
37
A short survey of dengue protease inhibitor development in the past 6 years (2015-2020) with an emphasis on similarities between DENV and SARS-CoV-2 proteases.
Birla Institute of Technology
6
The design and enzyme-bound crystal structure of indoline based peptidomimetic inhibitors of hepatitis C virus NS3 protease.
Mrl Rome
1
Nanoparticular Inhibitors of Flavivirus Proteases from Zika, West Nile and Dengue Virus Are Cell-Permeable Antivirals.
Freie Universit£T Berlin
5
Identification and In Silico Binding Study of a Highly Potent DENV NS2B-NS3 Covalent Inhibitor.
Shenyang Pharmaceutical University
11
P4 and P1' optimization of bicycloproline P2 bearing tetrapeptidyl alpha-ketoamides as HCV protease inhibitors.
Eli Lilly
18
P4 cap modified tetrapeptidyl alpha-ketoamides as potent HCV NS3 protease inhibitors.
Eli Lilly
6
Structural variations in keto-glutamines for improved inhibition against hepatitis A virus 3C proteinase.
University of Alberta
73
Synthesis, structure-activity relationship and antiviral activity of indole-containing inhibitors of Flavivirus NS2B-NS3 protease.
Baylor College of Medicine
11
Amidoxime prodrugs convert to potent cell-active multimodal inhibitors of the dengue virus protease.
Griffith University
47
Non-peptidic small-molecule inhibitors of the single-chain hepatitis C virus NS3 protease/NS4A cofactor complex discovered by structure-based NMR screening.
Schering-Plough Research Institute
10
The spectrum between substrates and inhibitors: Pinpointing the binding mode of dengue protease ligands with modulated basicity and hydrophobicity.
Heidelberg University
36
Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.
Vertex Pharmaceuticals
17
Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 2: tertiary amides.
Shire Biochem
19
Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 1: Sulfonamides.
Shire Biochem
11
NMR structural characterization of peptide inhibitors bound to the Hepatitis C virus NS3 protease: design of a new P2 substituent.
Boehringer Ingelheim (Canada)
16
Novel P4 truncated tripeptidyl alpha-ketoamides as HCV protease inhibitors.
Eli Lilly
12
P1 and P3 optimization of novel bicycloproline P2 bearing tetrapeptidyl alpha-ketoamide based HCV protease inhibitors.
Eli Lilly
16
Discovery of a novel bicycloproline P2 bearing peptidyl alpha-ketoamide LY514962 as HCV protease inhibitor.
Eli Lilly
28
SAR of novel benzothiazoles targeting an allosteric pocket of DENV and ZIKV NS2B/NS3 proteases.
Johannes Gutenberg-University
48
Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives.
Boehringer Ingelheim (Canada)
7
Application of the lambda-dynamics method to evaluate the relative binding free energies of inhibitors to HCV protease.
Schering-Plough Research Institute
2
Two antiviral compounds from the plant Stylogne cauliflora as inhibitors of HCV NS3 protease.
Schering-Plough Research Institute
53
Design and synthesis of pyrrolidine-5,5'-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 4. Antiviral activity and plasma stability.
Glaxosmithkline
9
Pyrimido[1,2-b]-1,2,4,5-tetrazin-6-ones as HCMV protease inhibitors: a new class of heterocycles with flavin-like redox properties.
Wyeth Research
20
Further SAR studies on novel small molecule inhibitors of the hepatitis C (HCV) NS5B polymerase.
Shire Biochem
52
Beyond Basicity: Discovery of Nonbasic DENV-2 Protease Inhibitors with Potent Activity in Cell Culture.
Heidelberg University
104
Synthesis, Structure-Activity Relationships, and Antiviral Activity of Allosteric Inhibitors of Flavivirus NS2B-NS3 Protease.
Baylor College of Medicine
7
Novel, potent phenethylamide inhibitors of the hepatitis C virus (HCV) NS3 protease: probing the role of P2 aryloxyprolines with hybrid structures.
Mrl Rome
27
Design and synthesis of potent, non-peptide inhibitors of HCV NS3 protease.
Bristol Myers Squibb
22
Glycine alpha-ketoamides as HCV NS3 protease inhibitors.
Pharmaceutical Research Institute
37
Design and synthesis of bicyclic pyrimidinone-based HCV NS3 protease inhibitors.
Bristol Myers Squibb
31
Phenethyl amides as novel noncovalent inhibitors of hepatitis C virus NS3/4A protease: discovery, initial SAR, and molecular modeling.
Mrl Rome
32
P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 protease.
Bristol Myers Squibb
19
Pyrrolidine-5,5-trans-lactams as novel mechanism-based inhibitors of human cytomegalovirus protease. Part 3: potency and plasma stability.
Glaxosmithkline
13
Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease.
Pfizer
20
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics.
Agouron Pharmaceuticals
41
Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease.
Schering-Plough Research Institute
30
Evolution, synthesis and SAR of tripeptide alpha-ketoacid inhibitors of the hepatitis C virus NS3/NS4A serine protease.
Irbm, Mrl Rome
8
Solution and solid-phase synthesis of potent inhibitors of hepatitis C virus NS3 proteinase.
Roche Discovery Welwyn
43
Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxohexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 2. Potency and chirality.
Glaxosmithkline
18
Discovery, total synthesis, HRV 3C-protease inhibitory activity, and structure-activity relationships of 2-methoxystypandrone and its analogues.
Merck Research Laboratories
26
Structure-activity relationship studies of a bisbenzimidazole-based, Zn(2+)-dependent inhibitor of HCV NS3 serine protease.
Bristol Myers Squibb
38
A New Class of Dengue and West Nile Virus Protease Inhibitors with Submicromolar Activity in Reporter Gene DENV-2 Protease and Viral Replication Assays.
Heidelberg University
6
Arylalkylidene rhodanine with bulky and hydrophobic functional group as selective HCV NS3 protease inhibitor.
Institute of Molecular and Cell Biology
2
Catching a Moving Target: Comparative Modeling of Flaviviral NS2B-NS3 Reveals Small Molecule Zika Protease Inhibitors.
Freie Universit£T Berlin
8
Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxo-hexahydro-pyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 1. The alpha-methyl-trans-lactam template.
Glaxo Wellcome Research and Development
4
Metal mediated protease inhibition: design and synthesis of inhibitors of the human cytomegalovirus (hCMV) protease.
Smithkline Beecham Pharmaceuticals
35
Synthesis of potent and broad genotypically active NS5B HCV non-nucleoside inhibitors binding to the thumb domain allosteric site 2 of the viral polymerase.
Idenix Sarl, An Msd
26
Substituted benzamide inhibitors of human rhinovirus 3C protease: structure-based design, synthesis, and biological evaluation.
Agouron Pharmaceuticals
11
Alpha-ketoamides, alpha-ketoesters and alpha-diketones as HCV NS3 protease inhibitors.
Dupont Pharmaceuticals
10
2-chloro-3-substituted-1,4-naphthoquinone inactivators of human cytomegalovirus protease.
Glaxowellcome Medicines Research Centre
10
Backbone modifications in peptidic inhibitors of flaviviral proteases.
Heidelberg University
12
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
Agouron Pharmaceuticals
12
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics.
Agouron Pharmaceuticals
12
Inhibition of human cytomegalovirus protease by enedione derivatives of thieno[2,3-d]oxazinones through a novel dual acylation/alkylation mechanism.
Smithkline Beecham Pharmaceuticals
34
Inhibition of herpes proteases and antiviral activity of 2-substituted thieno[2,3-d]oxazinones.
Smithkline Beecham Pharmaceuticals
10
Peptide-β-lactam Inhibitors of Dengue and West Nile Virus NS2B-NS3 Protease Display Two Distinct Binding Modes.
Heidelberg University
87
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.
Bristol Myers Squibb
4
Design and synthesis of dipeptidyl alpha',beta'-epoxy ketones, potent irreversible inhibitors of the cysteine protease cruzain.
University of Michigan
2
Prodrug Activation by a Viral Protease: Evaluating Combretastatin Peptide Hybrids To Selectively Target Infected Cells.
Heidelberg University
14
Design, Synthesis, and Anti-RNA Virus Activity of 6'-Fluorinated-Aristeromycin Analogues.
Seoul National University
30
Drugs for the Treatment of Zika Virus Infection.
University of North Carolina at Chapel Hill
15
Peptide derivatives as inhibitors of NS2B-NS3 protease from Dengue, West Nile, and Zika flaviviruses.
Federal University of Alagoas
9
Synthesis and structure-activity relationships of small-molecular di-basic esters, amides and carbamates as flaviviral protease inhibitors.
Heidelberg University
43
beta-Lactam derivatives as inhibitors of human cytomegalovirus protease.
Boehringer Ingelheim (Canada)
1
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.
Agouron Pharmaceuticals
18
Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements.
Agouron Pharmaceuticals
27
Proline-Based Allosteric Inhibitors of Zika and Dengue Virus NS2B/NS3 Proteases.
Johannes Gutenberg University Mainz
6
Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease.
Australian National University
57
Peptidomimetic inhibitors of the human cytomegalovirus protease.
Boehringer Ingelheim
20
Optimization of a fragment linking hit toward Dengue and Zika virus NS5 methyltransferases inhibitors.
Cnrs Umr7258
5
Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy.
Merck Research Laboratories
24
Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease.
Agouron Pharmaceuticals
3
Phenylthiomethyl Ketone-Based Fragments Show Selective and Irreversible Inhibition of Enteroviral 3C Proteases.
Freie Universit£T Berlin
62
2,3,4-Trihydroxybenzyl-hydrazide analogues as novel potent coxsackievirus B3 3C protease inhibitors.
Gwangju Institute of Science and Technology (Gist)
5
Achiral pyrazinone-based inhibitors of the hepatitis C virus NS3 protease and drug-resistant variants with elongated substituents directed toward the S2 pocket.
Uppsala University
2
Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2-P1' Region.
Uppsala University
1
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
Array Biopharma
25
Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors.
Merck Research Laboratories
9
Haloperidol-based irreversible inhibitors of the HIV-1 and HIV-2 proteases.
University of California
24
Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkers.
Merck Research Laboratories
14
Development of anti-coxsackievirus agents targeting 3C protease.
Gwangju Institute of School of Life Sciences
8
Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor.
Merck Research Laboratories
9
Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors.
Academia Sinica
5
Discovery of achiral inhibitors of the hepatitis C virus NS3 protease based on 2(1H)-pyrazinones.
Uppsala University
6
Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
Uppsala University
35
Novel inhibitors of dengue virus methyltransferase: discovery by in vitro-driven virtual screening on a desktop computer grid.
University of Basel
1
Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
Vertex Pharmaceuticals
1
Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha.
Vertex Pharmaceuticals
26
4-Iminooxazolidin-2-one as a Bioisostere of the Cyanohydrin Moiety: Inhibitors of Enterovirus 71 3C Protease.
Nankai University
24
Functionalized 2,1-benzothiazine 2,2-dioxides as new inhibitors of Dengue NS5 RNA-dependent RNA polymerase.
University of Perugia
17
Identification of quinone analogues as potential inhibitors of picornavirus 3C protease in vitro.
Korea Research Institute of Chemical Technology
21
Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication.
Umr 7273 Cnrs
8
Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity.
Chia Tai Tianqing Pharmaceutical Group
22
Discovery of Potent EV71 Capsid Inhibitors for Treatment of HFMD.
Wuxi Apptec (Shanghai)
14
Structure-based design and synthesis of macrocyclic human rhinovirus 3C protease inhibitors.
Novartis Institutes For Biomedical Research
25
Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530).
Abbvie
22
The discovery and optimization of naphthalene-linked P2-P4 Macrocycles as inhibitors of HCV NS3 protease.
Bristol Myers Squibb
11
Structure-activity relationship of uridine-based nucleoside phosphoramidate prodrugs for inhibition of dengue virus RNA-dependent RNA polymerase.
Novartis Institute For Tropical Diseases
13
Synthesis and antiviral evaluation of novel peptidomimetics as norovirus protease inhibitors.
Emory University
18
Imidazole derivative expressing FLT3 inhibitory activity, and use thereof
Industry-University Cooperation Foundation Hanyang University Erica Campus
8
Substituted pyrrolo[2,3-d]pyrimidines as inhibitors for multi-resistant cancers
Ferris State University
40
Imidazo[1′,2′:1,6]pyrido[2,3-d]pyrimidine compound as protein kinase inhibitor
Shengke Pharmaceuticals (Jiangsu)
28
Aryl ethene derivative and pharmaceutical composition containing same as active ingredient
Daegu-Gyeongbuk Medical Innovation Foundation
52
Imidazole and triazole containing bicyclic compounds as JAK inhibitors
Theravance Biopharma R&D Ip
378
Substituted 7-azabicycles and their use as orexin receptor modulators
Janssen Pharmaceutica
20
Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof
Shanghai Hengrui Pharmaceutical
61
Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Forma Therapeutics
37
Substituted indazole derivatives active as kinase inhibitiors
Nerviano Medical Sciences
47
Heterocyclic derivatives and their use in the treatment of neurological disorders
Novartis
97
Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer
Janssen Pharmaceutica
3
Nostotrebin 6, a bis(cyclopentenedione) with cholinesterase inhibitory activity isolated from Nostoc sp. str. Lukesová 27/97.
Brno University of Technology
9
Synthesis, in vitro evaluation and molecular docking studies of novel amide linked triazolyl glycoconjugates as new inhibitors of a-glucosidase.
Csir-Indian Institute of Chemical Biology
42
Small Molecules Engage Hot Spots through Cooperative Binding To Inhibit a Tight Protein-Protein Interaction.
Indiana University School of Medicine
30
Synthesis, structure-activity relationships studies of benzoxazinone derivatives as a-chymotrypsin inhibitors.
University of Karachi
17
Method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
Amicus Therapeutics
41
2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease
Albireo
44
Functionally selective ligands of dopamine D2 receptors
University of North Carolina at Chapel Hill
171
5,8-dihydro-6H-pyrazolo[3,4-h]quinazolines as IGF-1R/IR inhibitors
Boehringer Ingelheim International
440
Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
Kudos Pharmaceuticals
7
Esters of (acyloxymethyl)acrylamide, a pharmaceutical composition containing them, and their use as inhibitors of the thioredoxin—thioredoxin reductase system
Instytut Chemii Organicznej Polskiej Akademii Nauk
12
A photorhabdus natural product inhibits insect juvenile hormone epoxide hydrolase.
Goethe Universität Frankfurt
55
Pyrazolo[3,4-d]pyrimidine compounds and their use as PDE2 inhibitors and/or CYP3A4 inhibitors
Pfizer
3
Competitive inhibition of human poly(A)-specific ribonuclease (PARN) by synthetic fluoro-pyranosyl nucleosides.
University of Thessaly
8
Developing dual and specific inhibitors of dimethylarginine dimethylaminohydrolase-1 and nitric oxide synthase: toward a targeted polypharmacology to control nitric oxide.
The University of Texas
25
Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines.
Harvard University
1
Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes.
Aventis Pharma
7
Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor.
Virginia Commonwealth University
45
Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis.
St. Bartholomew'S and The Royal London School of Medicine and Dentistry
31
Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
Kyoto University
49
Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype.
National Institute of Neurological Disorders and Stroke
1
RS 39604: a potent, selective and orally active 5-HT4 receptor antagonist.
Syntex Discovery Research
3
Receptor binding profiles of amiloride analogues provide no evidence for a link between receptors and the Na+/H+ exchanger, but indicate a common structure on receptor proteins.
Center For Bio-Pharmaceutical Sciences
22
COMPOUND, METHOD OF PREPARATION, COMPOSITION, AND USES THEREOF
Amrita Vishwa Vidyapeetham
46
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
Universita Degli Studi Di Firenze
9
1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.
Nerviano Medical Sciences
2
3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy.
University of Bologna
10
Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors.
Shanghai Institute of Materia Medica
72
Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.
Eli Lilly
19
Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H- pyran-3-yl)thiomethanes that span P1-P2' subsites in a unique mode of active site binding.
Parke-Davis Pharmaceutical Research
10
Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant.
Sapienza University of Rome
6
Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies.
Sapienza University of Rome